Guardant Health Gets FDA Nod on Colorectal Cancer Blood Test

Shield is the first blood test that the FDA has approved as a primary screening option for colorectal cancer and the first that meets Medicare coverage performance requirements, the company said. The test is for adults age 45 and older who carry an average risk. FDA Approval Is 'Significant Victory' In a study, the Shield test showed 83% sensitivity in detecting colorectal cancer, including 90% specificity for advanced neoplasia, the company said. tips@investopedia.com Guardant Health's Shield blood test fo ...